RIGL
RIGEL PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$46.43
+1.26%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- $0.92
- Revenue estimate
- $80.1M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- $0.88
- EPS estimate
- $0.09
- Revenue actual
- $78.7M
- Revenue estimate
- $55.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +226.5%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $67
- PT range
- $49 – $85
- Analysts
- 2
1 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | $0.09 | $0.88 | Beat 903.88% | $78.7M |
| May 5, 2026 | $0.74 | $0.44 | Miss -40.54% | $58.8M |
| Mar 3, 2026 | $1.33 | $1.14 | Miss -14.29% | $69.8M |
| Nov 4, 2025 | $0.93 | $1.46 | Beat 56.99% | $69.5M |
| Mar 4, 2025 | $0.30 | $0.80 | Beat 166.67% | $57.6M |
| Nov 7, 2024 | $0.06 | $0.70 | Beat 1066.67% | $55.3M |
| Mar 5, 2024 | $0.02 | $0.04 | Beat 100.00% | $35.8M |
| Aug 1, 2023 | -$0.80 | -$0.40 | Beat 50.00% | $26.9M |
| May 2, 2023 | -$0.90 | -$0.80 | Beat 11.11% | $26.1M |
| Mar 7, 2023 | -$0.70 | $0.10 | Beat 114.29% | $51.3M |
| Nov 3, 2022 | -$1.30 | -$1.10 | Beat 15.38% | $22.4M |
| Aug 2, 2022 | -$1.20 | -$0.80 | Beat 33.33% | $29.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026